Gilead Makes Exclusive Deal With CVS for Hepatitis C Drugs
This article is for subscribers only.
Gilead Sciences Inc. agreed to make its hepatitis C medicines the exclusive treatments for CVS Health Corp. customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.
Gilead’s Harvoni and Sovaldi will be the only pills covered on CVS’s main list of drugs, as well as on its list for health plans through Obamacare, Medicare Part D and Medicaid, the benefits manager said today in an e-mail.